Update on the management of giant cell arteritis
Janet Roberts1, Alison Clifford2
1Division of Rheumatology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Abstract:
Giant cell arteritis (GCA) is a large vessel vasculitis that may be associated with significant complications such as blindness, stroke, or aortic aneurysm and dissection in a subset of patients. Given the serious side effects associated with prolonged courses of glucocorticoids and frequent relapses experienced when doses are tapered, increased efforts are being dedicated to the discovery of safer and more effective therapies to control this disease. The purpose of this review is to critically evaluate the role of glucocorticoid-sparing agents in the medical management of GCA with a special focus on the most recent evidence regarding the role of biologic agents, including tocilizumab (TCZ), abatacept and ustekinumab, and other novel therapies.
More Related Videos
04:50Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
07:21Microsurgical Creation of Giant Bifurcation Aneurysms in Rabbits for the Evaluation of Endovascular Devices
Published on: September 8, 2023
Related Concept Videos
Rheumatic Heart Disease III: Medical Management
Aneurysm III: Interprofessional Care
Aortic Regurgitation III: Medical Management
Atherosclerosis III: Management
Pericarditis III: Medical Management
Myocarditis III: Medical Management
